Purity
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its ability to bind fluorescein-conjugated S. aureus Bioparticles. Jiang, Y. et al. (2006) J. Biol. Chem. 281:11834. The ED 50 for this effect is 0.4-2 μg/mL.
Source
Human embryonic kidney cell, HEK293-derived
Human SR-BI
(Pro33-Tyr443)
Accession # CAA80277IEGRMD Human IgG1
(Pro100-Lys330)N-terminus C-terminus Accession #
N-terminal Sequence
AnalysisPro33
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
73 kDa
SDS-PAGE
84-115 kDa, reducing conditions
8114-SRB |
| |
Formulation Lyophilized from a 0.2 μm filtered solution in PBS. | ||
Reconstitution Reconstitute at 500 μg/mL in PBS. | ||
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. | ||
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Data Images
Bioactivity
| Recombinant Human SR-BI Fc Chimera (Catalog # 8114-SRB) binds to fluorescein-conjugated S. aureus Bioparticles with an ED50 of 0.4-2 μg/mL. |
Background: SR-BI
Scavenger Receptor, class B, member 1 (SR-BI), gene name SCARB1, is also known as CD36L1 (CD36-like 1) or CLA-1 (CD36 and LIMPII analogous 1) (1-5). SR-BI is a transmembrane glycoprotein found on macrophages, liver cells and other steroidogenic cells as a lipoprotein receptor. The 552 amino acid (aa) human SR-BI contains a central extracellular domain (ECD), flanked by N- and C-terminal transmembrane domains. Human splice variants differ at the N-terminal cytoplasmic and transmembrane domains (SR-BIII, 474 aa), the N-terminal end of the ECD (SR-BII, 409 aa), or the C-terminal cytoplasmic domain (isoform 3, 552 aa) (2). The human SR-BI ECD shares 80%, 80%, 89%, 86% and 84% aa sequence identity with mouse, rat, porcine, rabbit, and bovine SR-BI, respectively. SR-BI functions in reverse cholesterol transport (RCT), which is thought to be anti-atherogenic by facilitating transport of cholesteryl esters from macrophages back to the liver for degradation (3). In rodent hepatocytes, SR-BI is the main receptor mediating RCT, while human hepatocytes also express a second mediator, CETP (cholesteryl ester transfer protein) (3-5). The importance of SR-BI in humans is shown by human SR-BI genetic variants that alter lipid metabolism (3-7). For example, the P297S polymorphism lowers uptake of high-density lipoprotein (HDL) cholesterol in the liver and increases plasma HDL cholesterol (3-5). On endothelial cells, signaling through SR-BI activates nitric oxide production, which attenuates monocyte adhesion (6). On adrenocortical cells, SR-BI mediates uptake of cholesteryl esters from HDL for the synthesis of glucocorticoid hormones such as cortisol (3-5). On platelets, HDL binding to surface SR-BI inhibits aggregation and increases platelet survival time (3-5). On human ovarian granulosa cells, deficiency of SR-BI correlates with low fertility (3). SR-BI and its SR-BII isoform also bind bacterial lipopolysaccharides, facilitating uptake of various bacteria by cells such as peritoneal macrophages (8, 9). This uptake enhances inflammatory responses which, unless properly controlled, can result in sepsis (9-11).
References:
Calvo, D. and M. A. Vega (1993) J. Biol. Chem. 268:18929.
Swiss-Prot accession Q8WTV0
Chadwick, A.C. and D. Sahoo (2013) Curr. Opin. Endocrinol. Diabetes Obes. 20:124.
Hoekstra, M. et al. (2012) Curr. Opin. Lipidol. 23:127.
Vergeer, M. et al. (2011) N. Engl. J. Med. 364:136.
Guo, L. et al. (2011) J. Lipid Res. 52:2272.
Saddar, S. et al. (2012) Circ. Res. 112:140.
Vishnyakova, T.G. et al. (2006) Proc. Natl. Acad. Sci. USA 103:16888.
Baranova, I.N. et al. (2012) J. Immunol. 188:1371.
Leelahavanichkul, A. et al. (2012) J. Immunol. 188:2749.
Guo, L. et al. (2009) J. Biol. Chem. 284:19826.
Long Name:
Scavenger Receptor Class B, Member I
Entrez Gene IDs:
949 (Human); 20778 (Mouse); 25073 (Rat)
Alternate Names:
CD36 and LIMPII analogous 1; CD36 antigen (collagen type I receptor, thrombospondin receptor)-like 1; CD36 antigen; CD36L1; CD36L1scavenger receptor class B type 1; CLA1 CD36 antigen-like 1; CLA-1 HDLQTL6; CLA1; Collagen type I receptor, thrombospondin receptor-like 1; HDLQTL6; MGC138242; SCARB1; scavenger receptor class B type III; scavenger receptor class B, member 1; SRB1 scavenger receptor class B member 1; SR-B1; SRBI; SR-BI
